What is the cure rate of Axitinib?

Axitinib is an oral tyrosine kinase inhibitor mainly used to treat advanced renal cell carcinoma, especially in patients who have failed first-line therapy. It exerts anti-tumor effects by inhibiting vascular endothelial growth factor receptor (VEGFR), blocking the formation of new blood vessels in tumors, thereby controlling the growth and spread of cancer cells. Axitinib has shown good efficacy in multiple clinical studies and has been approved by many countries as a second-line treatment for renal cancer.

However, there is currently no evidence that axitinib can "cure" advanced renal cancer. Clinically, it is more commonly used to delay disease progression and improve progression-free survival (PFS) and overall survival (OS). According to the results of a pivotal AXIS study, the median progression-free survival in the axitinib group was 6.7 months, which was significantly better than the sorafenib group's 4.7 months. Some patients can achieve tumor shrinkage or even long-term stable disease, but the probability of complete cure is extremely low.

It is worth noting that the therapeutic effect of axitinib is affected by many factors, including the patient's physical condition, tumor stage, and whether it is combined with other targeted drugs or immunotherapy. In individual cases, some patients can achieve complete remission after combined immunotherapy, but this does not mean a true "cure" but more like long-term disease control. There is a strict definition of "cure" in medicine. For advanced tumors, only long-term no recurrence can be considered close to cure.

In summary, although axitinib cannot achieve a high "cure rate", it plays an important role in controlling the progression of advanced renal cancer and prolonging the survival of patients. Patients should fully communicate with their doctors before receiving treatment, choose the most appropriate treatment plan based on their individual conditions, and conduct regular reviews to maximize the efficacy and quality of life.

Reference materials:https://en.wikipedia.org/wiki/Axitinib